Cognition Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CGTX, updated each market day.
CGTX AI Sentiment
AI predicts Cognition Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Sector
Exchange
Market Cap
$76,862,115
Cap Tier
Employees
14
Headquarters
PURCHASE, NY
Listed Since
Oct. 8, 2021
Website
CGTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CGTX Volatility
Cognition Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
